Allen & Overy advises Meatable and Leyden Laboratories on their series A venture capital  investments

A team led by Christiaan de Brauw  with support from Sophie Roozendaal and Jort de Groodt advised:

1. Meatable on its USD47m series A preferred investment rounds in which a consortium of life sciences and food investors including Dr. Rick Klausner, Section 32, DSM Venturing, Dr. Jeffrey Leiden and existing investors support Meatable for its next phase of growth.
2. Leyden Laboratories on its EUR40m series A preferred investment round led by GV, with participation from F-Prime Capital, Casdin Capital, LLC and Brook Byers. The proceeds of the investment round will be used to further develop intranasal medicines intended to stop viruses before they infect the lungs (like Covid19). Leyden Labs’ platform and portfolio of product candidates target commonalities of viral families to protect against many viruses simultaneously, as opposed to vaccines that typically protect against a specific virus variant. (press coverage: Dutch and English)

Both these transactions showcase our ability to work efficiently and successfully on high-profile venture capital investments in the Netherlands. The broader team consisted of Berend Veenstra, Pauline van der Hijden and Aziz Bouhbouh (Leyden Laboratories only).